Participated · Series B · Oct 2025

Founded in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, OncoC4 leverages deep immuno-oncology expertise to create a pipeline of innovative biologic therapies with first-in-class or best-in-class potential. The Rockville, Maryland company is advancing multiple clinical-stage candidates that target both novel and well-validated pathways across oncology and immunological disorders. Its strategy centers on rigorous global clinical development complemented by active business development to broaden therapeutic reach. Although specific revenue or patient metrics were not disclosed, the company characterizes itself as having a broad pipeline poised for growth. Proceeds from its latest financing will fund continued clinical development of these pipeline programs. Management emphasizes a commitment to delivering disruptive therapies to patients worldwide. The company’s leadership team includes Dr. Yang Liu, who serves as Chairman, CEO, and CSO.

Participated · Series D · Jun 2024

Osteal Therapeutics is a clinical-stage biopharmaceutical company developing novel combination drug/device therapies to treat orthopedic infections and their consequences. Its lead candidate, VT-X7, is a seven-day vancomycin and tobramycin irrigation drug/device designed to deliver antibiotics directly to the joint space to treat periprosthetic joint infection (PJI). In clinical studies, 100% of patients were treated and received a new permanent joint prosthesis in seven days with more than 90% remaining infection-free after one year. VT-X7 has been evaluated in two multicenter randomized controlled trials, APEX and APEX-2; APEX met its primary endpoint in 2023 and APEX-2 recently met its primary endpoint and will be completed in late 2024. The FDA has granted VT-X7 Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations, and the company expects to seek approval upon APEX-2 completion. Osteal leverages locally delivered, concentrated antimicrobials and repurposes approved drugs for new local-delivery routes to address biofilm-driven musculoskeletal infections. Osteal Therapeutics is a Dallas, TX-based clinical-stage biopharmaceutical company developing musculoskeletal therapeutics to treat orthopedic infections and their consequences. Its lead candidate, VT-X7, is a locally delivered antimicrobial in Phase 2 development aimed at treating periprosthetic joint infections (PJI). The company leverages concentrated, locally delivered antimicrobials to combat bacterial biofilms while minimizing off-target tissue exposure and adverse effects. Osteal employs a low-risk development approach by repurposing approved drugs with known safety and efficacy profiles for new routes of local delivery. It recently closed a $23M Series C financing to fund its next steps. Proceeds will support an NDA submission to the FDA and accelerate preparation for VT-X7's commercial launch; the company is led by CEO and President David Thompson. Osteal Therapeutics is a clinical-stage biopharmaceutical company creating a new category of combination therapies to treat musculoskeletal infections by delivering concentrated, locally applied antimicrobials to target biofilms. Its lead candidate, VT-X7, is a drug/device combination (vancomycin HCl and tobramycin sulfate for irrigation) designed as a seven-day therapy to deliver antibiotics directly to the joint space and surrounding tissue to treat chronic periprosthetic joint infection (PJI). VT-X7 completed an open-label Phase 2 trial in which 100% of VT-X7 patients were treated and received a new permanent joint prosthesis in seven days and 93% remained infection-free at one year. The company is currently enrolling APEX, a randomized controlled study of VT-X7 versus the current standard of care (two-stage exchange arthroplasty). The FDA has granted VT-X7 Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations. Osteal plans to use new capital to advance VT-X7 into later-stage clinical trials and to fund additional research programs.

Participated · Series B · Aug 2022

Porton Advanced Solutions is a Suzhou, China-based CDMO dedicated to gene and cell therapy (GCT) development and manufacturing. The company provides an integrated GCT CDMO platform covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy. It currently operates a 40,000 sqft R&D and GMP production facility that has been in operation for over two years and has delivered plasmids, viruses and cell batches to sponsors. Porton Advanced plans to bring a 160,000 sqft commercial production facility online in late 2022/early 2023, bringing total PD, AD and GMP manufacturing to over 200,000 sqft. The firm intends to scale capacity to support AAV, oncolytic virus and mRNA CDMO capabilities, and will deploy proceeds to expand into different markets, invest in core manufacturing infrastructure and build global commercial operations. The company is led by CEO Dr. Wang Yangzhou.

Participated · Series C · Jan 2022

GenFleet Therapeutics is a clinical-stage biotechnology company based in Shanghai focused on developing cutting-edge therapies in oncology and immunology. The company has a proprietary R&D and discovery platform and is developing both small molecules and biologics. Its diversified pipeline includes over 10 products, many of which have progressed into clinical stages. GenFleet is expanding clinical trials in China, the United States and Australia and expects more programs to move into late-stage clinical development in 2022. Management says proceeds will support global development of clinical-stage programs, build a broader portfolio of innovative programs, and accelerate commercialization over the coming years. GenFleet Therapeutics develops new drug candidates and is stepping into global multi-center clinical trials. The company announced a Series B+ financing in the hundreds of millions of RMB to speed development of its existing products and the conduct of its clinical trials. It plans to create an international cutting‑edge R&D system and open its industrial layout in parallel. Proceeds will be used to continually complete milestones of its "global new" drug development. The financing marks a new development stage focused on accelerating clinical programs and building international capabilities. DeHeng Law Offices acted as legal counsel on the transaction. GenFleet Therapeutics develops small-molecule therapeutics for immuno-oncology. The company’s first product entered IND application stage just over one year after the program was launched. Proceeds from its latest financing are intended to advance the IND application and subsequent clinical development of that program. GenFleet says it is executing projects rapidly and expanding its pipeline and business functions. Leadership has stated the company aims to become a pioneer in immuno-oncology and to build an innovative, balanced product portfolio to address unmet needs. The company is based in Shanghai, China.

Participated · Equity · Feb 2021

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target dysfunctional metabolic pathways to treat diseases including NASH and specific cancers. The company is advancing TVB-2640, an oral, first-in-class fatty acid synthase (FASN) inhibitor, and plans a Phase 2b trial evaluating histological endpoints. In its Phase 2 randomized placebo-controlled FASCINATE-1 trial, TVB-2640 significantly decreased liver fat and improved serum biomarkers of liver injury, fibrosis and inflammation in NASH patients. Sagimet also intends to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021. The company is led by CEO George Kemble, PhD, and is based in San Mateo, California. It is using recent financing to advance its lead program and explore additional indications. Sagimet Biosciences is a San Mateo, Calif.-based clinical-stage biopharmaceutical company led by George Kemble, PhD, CEO and CSO. The company focuses on developing novel therapeutics that target dysfunctional metabolic pathways to treat NASH and specific cancers. Its lead candidate is TVB-2640, an orally bioavailable, first-in-class FASN inhibitor targeting de novo lipogenesis (DNL) to reduce excess liver fat in NASH patients. Sagimet will use the recently raised funds to continue advancing TVB-2640 through clinical development. The company has completed a second tranche of its Series E financing, bringing the round to $25M in total. Prior funding activity in the Series E included an initial $18M funded in February 2019. No revenue or user metrics were reported in the article. 3-V Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target dysfunctional metabolic pathways, including the FASN inhibitor TVB-2640 (ASC40). TVB-2640 is described as a first-in-class, orally bioavailable FASN inhibitor and a Phase 2-ready drug candidate for non-alcoholic steatohepatitis (NASH). The company plans Phase 2 multi-center trials of TVB-2640 in the United States and China and will evaluate the drug's impact on liver fat using advanced imaging techniques. In conjunction with the financing, 3-V Biosciences granted an exclusive license to Ascletis to develop, manufacture and commercialize ASC40 (TVB-2640) in Greater China. Under that license 3-V Biosciences is eligible to receive development and commercial milestones as well as tiered royalties on future net sales. Financially, 3-V Biosciences raised US$18 million in a Series E financing and has commitments for an additional US$7 million in a subsequent financing to support continued development of TVB-2640. 3-V Biosciences is a Menlo Park-based biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. Its lead candidate, TVB-2640, is an oral proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors. The company is advancing oncology clinical trials both as monotherapy and in combination with cytotoxic agents, including phase IB expansion cohorts. It also has a second program in preclinical and IND-enabling stages with plans to file for regulatory (IND or CT) clearance in 2015. 3-V is led by CEO Merdad Parsey, M.D., Ph.D. Financially, the company closed a $28.5M Series D to support these oncology programs. 3-V Biosciences discovers and develops therapeutics that target key pathways in oncology and infectious disease. Its lead oncology candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. The company is also evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV). 3-V intends to use the funds from its financing to advance its lead oncology candidate into a Phase 1 clinical trial and to support ongoing preclinical studies of multiple virology leads generated by its integrated drug discovery process. The company completed a $20m Series C financing, and backers included existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates. Merdad Parsey, M.D., Ph.D., serves as Chief Executive Officer.